Advances in the application of nanocarriers in colorectal cancer treatment
- 1First Clinical Medical College, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
- 2Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China;
Abstract
The current comprehensive treatment system for colorectal cancer (CRC), which is primarily based on surgery and supplemented by chemotherapy, radiotherapy, and targeted therapy, still faces several bottlenecks, including significant toxic side effects of chemotherapeutic agents, reduced chemosensitivity due to multiple drug resistance (MDR) mechanisms, and dependence of targeted therapy on specific gene mutations, resulting in limited overall efficacy. Nanocarriers, through strategies such as active targeting modifications, tumor microenvironment-responsive drug release, and co-loading of multiple therapeutic agents, can partially overcome the insufficient penetration efficiency of passive targeting imposed by the dense stromal barrier of tumor tissues, thereby offering a novel pathway for precision drug delivery distinct from conventional passive targeting approaches. This review systematically summarizes the research progress of various nanocarriers in CRC therapy, analyzes common factors hindering clinical translation based on translational data from representative nanomedicine formulations, and proposes future directions from perspectives including molecular subtype-guided individualized design, oral targeted delivery, and multimodal combination therapy, with the aim of providing references for both fundamental research and clinical translation of nanodrug delivery systems for CRC.
Related
- Recent Advances in Small-Molecule-Based Nanovectors for the Treatment of Colorectal Cancer
- Ligand-functionalized nanocarriers for targeted breast cancer therapy: advances in receptor-mediated drug delivery
- Imatinib in the Treatment of Colorectal Cancer—Molecular Targets, Preclinical Evidence and Clinical Limitations
- Redox-Responsive Polymeric Nanocarriers for Targeted Delivery of Bruceantin to Pancreatic Cancer
- Tumor microenvironment-responsive manganese nanocarriers for on-demand release of methotrexate and DNAzyme in MiR-155-driven cervical cancer.
BibTeX
@article{guangquan2026advances,
title = {{Advances in the application of nanocarriers in colorectal cancer treatment}},
author = {Qin Guangquan and Chen Lifa and Luo Deyan and Qin Hancheng and Guo Yun and Huang Jiahao},
journal = {结直肠肛门外科},
year = {2026},
month = aug,
doi = {10.19668/j.cnki.issn1674-0491.2026.04.017},
url = {https://doi.org/10.19668/j.cnki.issn1674-0491.2026.04.017},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Advances in the application of nanocarriers in colorectal cancer treatment
AU - Qin Guangquan
AU - Chen Lifa
AU - Luo Deyan
AU - Qin Hancheng
AU - Guo Yun
AU - Huang Jiahao
PY - 2026
DA - 2026/08/01
JO - 结直肠肛门外科
DO - 10.19668/j.cnki.issn1674-0491.2026.04.017
UR - https://doi.org/10.19668/j.cnki.issn1674-0491.2026.04.017
AB - The current comprehensive treatment system for colorectal cancer (CRC), which is primarily based on surgery and supplemented by chemotherapy, radiotherapy, and targeted therapy, still faces several bottlenecks, including significant toxic side effects of chemotherapeutic agents, reduced chemosensitivity due to multiple drug resistance (MDR) mechanisms, and dependence of targeted therapy on specific gene mutations, resulting in limited overall efficacy. Nanocarriers, through strategies such as active targeting modifications, tumor microenvironment-responsive drug release, and co-loading of multiple therapeutic agents, can partially overcome the insufficient penetration efficiency of passive targeting imposed by the dense stromal barrier of tumor tissues, thereby offering a novel pathway for precision drug delivery distinct from conventional passive targeting approaches. This review systematically summarizes the research progress of various nanocarriers in CRC therapy, analyzes common factors hindering clinical translation based on translational data from representative nanomedicine formulations, and proposes future directions from perspectives including molecular subtype-guided individualized design, oral targeted delivery, and multimodal combination therapy, with the aim of providing references for both fundamental research and clinical translation of nanodrug delivery systems for CRC.
SN - 1674-0491
ER -